Carbios set to build closed-loop PET plant
French Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios groundbreaking enzymatic PET depolymerisation […]
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Adrenomed bags 24m in growth financing
/in News/by Thomas GabrielczykGerman Adrenomed AG has bagged 24m in equity financing from HBM Healthcare Investments and Wellington Partners.
Roche targets asthma with inhalable JAK1 blocker
/in News/by Thomas GabrielczykResearchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.
British F2G Biotech bags 24m
/in News/by Thomas GabrielczykThe European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd 24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
Sugar replacement slows cancer growth
/in News/by Thomas GabrielczykResearchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Epigenetic drugs can increase tumour malignancy
/in News/by Thomas GabrielczykResearchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Mittwoch: Epigenetic drugs can increase tumour malignancy
/in News/by Thomas GabrielczykResearchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Forbion leads 40m financing in Inflazome Ltd
/in News/by Thomas GabrielczykInflammosome inhibitor specialist Inflazome Ltd has raised 40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
Boehringer and Epizyme enter US$300m deal
/in News/by Thomas GabrielczykBoehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Breakthrough in restless legs syndrome
/in News/by Thomas GabrielczykResearchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.